Abstract: Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy in cancer treatment. However, immune-related adverse events (irAEs) remain a key challenge in clinical practice. Based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results